Eczema (Atopic Dermatitis)

What is Eczema (Atopic Dermatitis)?

Eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed patches of skin. It is the most common form of eczema and typically begins in early childhood, though it can develop at any age. Atopic dermatitis affects millions of people worldwide and is often associated with other allergic conditions such as asthma and hay fever. The condition follows a relapsing and remitting course, with periods of flare-ups alternating with times of relative calm.

Key statistics

Symptoms

Common symptoms include: intense itching, red inflamed skin, dry scaly patches, skin thickening, small raised bumps, oozing or crusting, sleep disruption due to scratching.

Early symptoms typically appear as red, dry patches on the cheeks, forehead, or scalp in infants. The affected areas may appear slightly swollen and feel warm to the touch. Intense itching often leads to scratching, which can worsen the inflammation.

Common presentation varies by age group. In children, eczema commonly affects the creases of elbows and knees, neck, wrists, and ankles. The skin becomes thickened and leathery from chronic scratching. In adults, eczema may affect the hands, eyelids, and flexural areas, often appearing as coin-shaped patches.

Submit Your Paper

Severe symptoms include widespread inflammation covering large body areas, secondary bacterial infections from scratching, severe sleep disruption affecting daily functioning, and emotional distress. Some patients develop eczema herpeticum, a serious viral infection that requires immediate medical attention.

Causes and risk factors

Atopic dermatitis results from a complex interaction between genetic predisposition, immune system dysfunction, and environmental factors. The condition involves a defective skin barrier that allows irritants and allergens to penetrate more easily while moisture escapes, leading to dry, inflamed skin.

Genetic factors play a significant role, with mutations in the filaggrin gene being particularly important. This protein helps maintain the skin’s protective barrier. Family history strongly influences risk, with children having a 50-70% chance of developing eczema if both parents are affected.

Environmental risk factors include exposure to allergens such as dust mites, pet dander, pollen, and certain foods. Irritants like harsh soaps, detergents, fragrances, and synthetic fabrics can trigger flare-ups. Climate factors, particularly low humidity and extreme temperatures, also contribute to symptom development.

Immune system factors involve an overactive inflammatory response, with increased production of certain immune cells and inflammatory substances that perpetuate the cycle of inflammation and itching.

Prevention

While atopic dermatitis cannot be completely prevented due to its genetic component, several evidence-based strategies can reduce the risk of development and minimize flare-ups. Early and consistent moisturizing in high-risk infants may help prevent the onset of eczema. Studies suggest that daily application of emollients from birth until six months of age can reduce eczema development by up to 50% in high-risk children.

Primary prevention strategies include maintaining optimal skin hydration through regular use of fragrance-free moisturizers, avoiding known irritants and allergens, and maintaining a humid environment. For families with a history of allergic diseases, exclusive breastfeeding for the first four to six months may provide some protection.

Secondary prevention focuses on identifying and avoiding personal triggers, maintaining a consistent skincare routine, and managing stress levels, which can worsen symptoms. Environmental modifications such as using hypoallergenic bedding, maintaining indoor humidity between 40-50%, and choosing appropriate clothing materials can significantly reduce flare-up frequency.

Complications

Without proper management, atopic dermatitis can lead to several serious complications that significantly impact quality of life. Secondary bacterial infections, particularly with Staphylococcus aureus, are common due to breaks in the skin from scratching. These infections may require antibiotic treatment and can lead to more widespread skin involvement.

Eczema herpeticum is a potentially serious viral infection caused by herpes simplex virus that can spread rapidly across eczematous skin. This condition requires immediate antiviral treatment and may necessitate hospitalization in severe cases.

Long-term complications include permanent skin changes such as lichenification (thickening and darkening of skin), scarring from chronic scratching, and increased susceptibility to contact dermatitis. Sleep disturbance is nearly universal in active eczema, leading to fatigue, poor concentration, and behavioral problems in children.

Psychosocial complications are significant, with higher rates of anxiety, depression, and social isolation among patients with moderate to severe eczema. The visible nature of the condition can lead to self-consciousness and reduced participation in social and physical activities.

Diagnosis

Atopic dermatitis is primarily diagnosed based on clinical criteria, as there is no single diagnostic test for the condition. The Hanifin and Rajka criteria are commonly used, requiring the presence of itchy skin plus three or more major criteria (typical morphology and distribution, chronic or relapsing course, personal or family history of atopic disease) and three or more minor criteria.

Clinical assessment includes detailed medical and family history, physical examination of affected skin areas, and evaluation of symptom patterns. Healthcare providers use scoring systems such as the Eczema Area and Severity Index (EASI) or SCORing Atopic Dermatitis (SCORAD) to assess disease severity.

Additional testing may include specific IgE testing to identify allergic triggers, though this is not diagnostic for eczema itself. Skin prick tests or patch testing may help identify contact allergens. In some cases, skin biopsy may be performed to rule out other conditions, though this is rarely necessary for typical presentations.

Differential diagnosis includes other forms of eczema, psoriasis, seborrheic dermatitis, and contact dermatitis. In infants, conditions such as seborrheic dermatitis and diaper dermatitis must be considered.

Treatment

Treatment of atopic dermatitis follows a stepwise approach based on disease severity, with the goals of reducing inflammation, controlling symptoms, and preventing flare-ups. The foundation of all treatment regimens is consistent moisturizing and trigger avoidance.

Topical therapies form the cornerstone of treatment. Hydrocortisone and other topical corticosteroids are first-line anti-inflammatory treatments, with potency selected based on severity and location. Topical calcineurin inhibitors such as tacrolimus and pimecrolimus are effective alternatives, particularly for sensitive areas like the face and neck.

Systemic treatments are reserved for moderate to severe cases. Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 pathways, has revolutionized treatment for severe atopic dermatitis. Traditional systemic immunosuppressants include methotrexate, cyclosporine, and azathioprine.

Emerging therapies include JAK inhibitors such as baricitinib and topical ruxolitinib. Phototherapy with narrowband UV-B light can be beneficial for widespread disease in adolescents and adults.

Adjunctive treatments include antihistamines for itch relief, though evidence for effectiveness is limited. Wet wrap therapy and dilute bleach baths may help in certain situations.

Prognosis

The prognosis for atopic dermatitis varies significantly among individuals, with many children experiencing improvement or resolution of symptoms as they age. Approximately 60% of children with eczema will see significant improvement by adolescence, though some degree of skin sensitivity often persists.

Factors influencing prognosis include age of onset, severity at presentation, family history of atopic diseases, and presence of other allergic conditions. Early-onset severe eczema is more likely to persist into adulthood. The development of asthma and allergic rhinitis, known as the “atopic march,” occurs in 30-50% of children with moderate to severe eczema.

Adult-onset eczema tends to be more persistent and may require long-term management. However, with appropriate treatment, most patients can achieve good symptom control and maintain normal quality of life.

Long-term outcomes are generally favorable with proper management. Life expectancy is not affected, though quality of life can be significantly impacted without adequate treatment. Early intervention and consistent management can prevent many complications and improve long-term outcomes.

Quality of life

Living with atopic dermatitis requires developing effective daily management strategies to minimize symptoms and prevent flare-ups. Establishing a consistent skincare routine is essential, including gentle cleansing with lukewarm water and fragrance-free cleansers, followed immediately by application of moisturizer to damp skin.

Dietary considerations may be important for some individuals, particularly those with identified food allergies. Common trigger foods include eggs, milk, nuts, and wheat, though elimination diets should only be undertaken with medical supervision. Maintaining a food diary can help identify personal triggers.

Clothing and environment modifications include choosing soft, breathable fabrics like cotton, avoiding wool and synthetic materials, washing clothes with hypoallergenic detergents, and maintaining appropriate humidity levels in the home. Stress management through relaxation techniques, regular exercise, and adequate sleep can significantly impact symptom severity.

Skin protection strategies include keeping fingernails short to minimize scratching damage, using gentle patting motions instead of rubbing when drying skin, and applying cold compresses during flare-ups for itch relief.

Mental health support is crucial, as the visible nature of eczema can impact self-esteem and social functioning. Counseling, support groups, and stress management techniques can be beneficial components of comprehensive care.

Pregnancy and fertility

Atopic dermatitis does not directly affect fertility in men or women. However, pregnancy can influence the course of eczema, with approximately one-third of women experiencing worsening, one-third improving, and one-third remaining stable during pregnancy.

Medication safety during pregnancy requires careful consideration. Most topical corticosteroids are considered safe when used as directed, though ultra-high potency preparations should be avoided. Topical calcineurin inhibitors have limited safety data and should be used cautiously. Systemic treatments like dupilumab have limited pregnancy data, and decisions should involve careful risk-benefit discussions.

Genetic counseling may be beneficial for families with strong histories of atopic diseases. The risk of transmitting eczema to offspring is significant when parents are affected, though this does not typically influence reproductive decisions given the condition’s manageability.

Postpartum considerations include the potential for symptom changes during breastfeeding and the importance of continuing safe treatment regimens. Most topical treatments are compatible with breastfeeding.

Children

Atopic dermatitis in children requires special consideration due to its impact on growth, development, and family functioning. The condition typically begins in infancy, with 45% of cases developing within the first six months of life and 85% by age five.

Presentation differences vary by age group. In infants, eczema commonly affects the face, scalp, and extensor surfaces. Toddlers and older children typically develop eczema in flexural areas such as elbow and knee creases. Adolescents may experience hand eczema and facial involvement.

School considerations include educating teachers and staff about the condition, ensuring access to moisturizers and medications, and addressing potential bullying or social issues. Some children may require accommodations for severe flare-ups affecting attendance or concentration.

Growth and development can be impacted by sleep disruption and, rarely, by prolonged use of potent topical corticosteroids. Regular monitoring of growth parameters is important in children requiring extensive topical steroid use.

Transition to adult care should begin in adolescence, with gradual transfer of self-management responsibilities and eventual transition to adult dermatology services around age 16-18.

When to see a doctor

Immediate medical attention is required for signs of serious infection, including fever, widespread redness and swelling, pus or yellow crusting, red streaking from affected areas, or worsening despite treatment. Eczema herpeticum, characterized by clusters of small blisters or erosions, requires urgent antiviral treatment.

Routine medical care should be sought when over-the-counter treatments are ineffective, symptoms interfere with sleep or daily activities, or when new or changing skin lesions appear. Regular follow-up with a dermatologist is important for moderate to severe cases.

Specialist referral may be appropriate for difficult-to-control eczema, suspected contact allergies requiring patch testing, or when systemic treatments are being considered. Allergist consultation can be valuable for identifying and managing allergic triggers.

Emergency situations include signs of severe infection, difficulty breathing (which may indicate anaphylaxis to a trigger), or severe, sudden worsening of widespread eczema.

Regional context

Limited specific data exists regarding atopic dermatitis prevalence in the Caucasus region, though international studies suggest prevalence rates similar to other temperate climate regions. Environmental factors specific to the region, including climate variability and potential occupational exposures, may influence disease patterns.

Healthcare access and treatment availability may vary across Georgia, Armenia, and Azerbaijan, with urban centers typically having better access to specialist care and newer treatments like biologics. Traditional medicine practices in the region should be discussed with healthcare providers to ensure compatibility with evidence-based treatments.

GMJ welcomes contributions from regional researchers to build the evidence base for atopic dermatitis in the Caucasus, particularly regarding environmental triggers, treatment accessibility, and cultural factors affecting disease management.

Research and clinical trials

Current research in atopic dermatitis focuses on developing new targeted therapies, understanding the skin microbiome’s role, and improving patient-reported outcome measures. JAK inhibitors represent a rapidly expanding treatment class, with several oral and topical formulations in development.

Emerging therapies include IL-13 antagonists, IL-31 receptor antagonists, and novel topical anti-inflammatory agents. Microbiome-based therapies and personalized medicine approaches based on genetic profiling are areas of active investigation.

Clinical trials are widely available for moderate to severe eczema that has not responded adequately to standard treatments. Patients can search for trials at ClinicalTrials.gov using terms like “atopic dermatitis,” “eczema,” or specific drug names.

Biomarker research aims to identify predictors of treatment response and disease progression, potentially enabling more personalized treatment approaches in the future.

Frequently asked questions

Is eczema contagious?

No, eczema is not contagious and cannot be transmitted from person to person through contact. However, secondary bacterial infections that can develop in eczematous skin may be contagious.

Will my child outgrow eczema?

Many children with eczema experience significant improvement or resolution by adolescence, with approximately 60% seeing substantial improvement. However, some degree of skin sensitivity often persists into adulthood.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.